Full-Time
Develops tubeless insulin delivery systems
$163.1k - $244.6k/yr
Senior, Expert
California, USA
Requires on-site work from an Insulet office at least 1x/week; may work remotely other days.
Insulet Corporation develops medical devices aimed at simplifying life for people with diabetes. Their main product, the Omnipod Insulin Management System, is a tubeless device that delivers insulin continuously for up to three days without needles. The Omnipod 5 Automated Insulin Delivery System integrates with a continuous glucose monitor, allowing users to manage blood sugar without multiple injections or fingersticks. Insulet differentiates itself by providing a user-friendly solution that enhances insulin management, with the goal of improving the quality of life for individuals with diabetes.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Acton, Massachusetts
Founded
2000
Help us improve and share your feedback! Did you find this helpful?
Remote Work Options
Insulet (NasdaqGS:PODD) launches Omnipod 5 iPhone App with Dexcom G7 compatibility - Simply Wall St news.
Insulet has launched a humorous paid social campaign for its wearable Omnipod 5 insulin delivery system - and teamed with Marvel for a stigma-busting comic book starring a teen heroine with diabetes.
Insulet Corp. (PODD), a medical device company, on Monday announced that Chief Executive Officer Jim Hollingshead has resigned from the Board of Directors.
Ashley McEvoy has been tapped to be president and CEO of Insulet.
Insulet competes with companies like DexCom, Tandem Diabetes Care, and Masimo Corporation in the diabetes care market.